Table Of Contents
1 Introduction 21
1.1 Overview Of North America Injectable Drug Delivery Market 21
1.2 Currency And Pricing 22
1.3 Limitation 22
1.4 Markets Covered 23
2 Market Segmentation 26
2.1 Markets Covered 26
2.2 Geographic Scope 27
2.3 Years Considered For The Study 28
2.4 Currency And Pricing 28
2.5 Research Methodology 29
2.6 Primary Interviews With Key Opinion Leaders 32
2.7 Secondary Sources 33
2.8 Assumptions 33
3 Market Overview 34
3.1 Drivers 36
3.1.1 Rising Cases Of Chronic Diseases 36
3.1.2 Rising Demand Of Self-Injection Devices 38
3.1.3 Growth Of Biologics Market 38
3.1.4 Technological Advancements And Innovations In Drug Delivery Market 39
3.2 Restraints 40
3.2.1 Needlestick Injuries And Infections 40
3.2.2 High Cost Of Development 41
3.2.3 Strict Regulatory Framework 42
3.3 Opportunity 43
3.3.1 Increasing Demand For Generic And Biosimilar Drugs 43
3.3.1.1 Generics 43
3.3.1.2 Biosimilars 43
3.3.2 Increasing Demand For Contraceptive Injectables 44
3.3.3 Increasing Demand For Self-Administration Of Drugs 45
3.4 Challenges 46
3.4.1 Alternative Route Of Drug Administration 46
3.4.2 Product Recall 47
3.4.3 Stability Of Products 47
3.4.4 Sterility Of Injections 48
4 Executive Summary 49
5 Premium Insights 51
6 North America Injectable Drug Delivery Market, By Type 54
6.1 Overview 55
6.2 Injectable Drug Delivery Devices 56
6.2.1 Conventional Injection Devices 57
6.2.1.1 Conventional Injection Devices, By Material 59
6.2.1.1.1 Glass 59
6.2.1.1.2 Plastic 59
6.2.1.2 Conventional Injection Devices, By Product 60
6.2.1.2.1 Fillable Syringes 60
6.2.1.2.2 Prefilled Syringes 61
6.2.1.3 Conventional Injection Devices, By Usability 62
6.2.1.3.1 Reusable Syringes 62
6.2.1.3.2 Disposable Syringes 62
6.2.2 Self Injection Devices 63
6.2.2.1 Needle Free Injectors (Nfi) 64
6.2.2.2 Needle Free Injectors, By Product 65
6.2.2.2.1 Fillable Needle-Free Injectors 65
6.2.2.2.2 Prefilled Needle-Free Injectors 65
6.2.2.3 Needle Free Injectors, By Technology 66
6.2.2.3.1 Jet Based Needle Free Injectors; 66
6.2.2.3.2 Spring Based Needle Free Injectors; 67
6.2.2.3.3 Laser Based Needle Free Injectors; 67
6.2.2.3.4 Vibration Based Needle Free Injectors; 67
6.2.2.4 Needle Free Injectors, By Usability 68
6.2.2.4.1 Reusable Needle-Free Injectors 68
6.2.2.4.2 Disposable Needle-Free Injectors 68
6.2.2.5 Auto Injectors 69
6.2.2.6 Auto Injectors, By Product 70
6.2.2.6.1 Fillable Auto Injectors 70
6.2.2.6.2 Pre-Filled Autoinjectors 70
6.2.2.7 Auto Injectors, By Technology 71
6.2.2.7.1 Automated Auto Injectors 71
6.2.2.7.2 Manual Auto Injectors 71
6.2.2.8 Auto Injectors, By Design 73
6.2.2.8.1 Standardized Auto Injectors 73
6.2.2.8.2 Automated Autoinjectors 73
6.2.2.9 Auto Injectors, By Usability 74
6.2.2.9.1 Reusable Autoinjectors 74
6.2.2.9.2 Disposable Autoinjectors 74
6.2.2.10 Pen Injectors 75
6.2.2.11 Pen Injectors, By Product 75
6.2.2.11.1 Single Chambered Pen Injectors 75
6.2.2.11.2 Dual Chambered Pen Injectors 76
6.2.2.12 Pen Injectors, By Design 76
6.2.2.12.1 Standard Pen Injectors 76
6.2.2.12.2 Customized Pen Injectors 77
6.2.2.13 Pen Injectors, By Usability 77
6.2.2.13.1 Reusable Pen Injectors 77
6.2.2.13.2 Disposable Pen Injectors 78
6.2.2.14 Wearable Injectors 78
6.2.2.14.1 Other Devices 79
6.3 Injectable Drug Delivery Formulation 80
6.3.1 Conventional Drug Delivery Formulations 81
6.3.1.1 Solutions 81
6.3.1.2 Reconstituted/Lyophilized Formulations 81
6.3.1.3 Suspensions 82
6.3.1.4 Emulsions 83
6.3.2 Novel Drug Delivery Formulations 85
6.3.2.1 Colloidal Dispersions 86
6.3.2.1.1 Niosomes 86
6.3.2.1.2 Liposomes 87
6.3.2.1.3 Polymeric Mixed Micelles 88
6.3.2.1.4 Nanoparticles 89
6.3.2.1.5 Nanosuspensions 89
6.3.2.1.6 Nanoemulsions/Microemulsions 90
6.3.2.1.7 Solid Lipid Nanoparticles 91
6.3.2.2 Microparticles 92
6.3.2.2.1 Microspheres 92
6.3.2.2.2 Microcapsules 93
6.3.2.3 Long Acting Injection Formulation 94
?
7 North America Injectable Drug Delivery Market, By Application 96
7.1 Overview 97
7.2 North America Injectable Drug Delivery Market, By Application 98
7.3 Hormonal Disorders 99
7.3.1 Injectable Drugs For Diabetes 99
7.3.2 Injectable Drugs For Anemia 100
7.3.3 Injectable Drugs For Reproductive Health Disease 102
7.3.4 Injectable Drugs For Antithrombotic/Thrombolytic Therapy 103
7.3.5 Injectable Drugs For Osteoporosis 103
7.3.6 Injectable Drugs For Growth Hormone Disorders (Ghd) 104
7.4 Oncology 106
7.5 Autoimmune Diseases 108
7.5.1 Injectable Drugs For Rheumatoid Arthritis 108
7.5.2 Injectable Drugs For Multiple Sclerosis 109
7.5.3 Injectable Drugs For Crohn?S Diseases 110
7.5.4 Injectable Drugs For Psoriasis 111
7.5.5 Injectable Drugs For Other Autoimmune Diseases 112
7.6 Orphan Disease 113
7.7 Other Applications 115
7.7.1 Injectable Drugs For Pain Management 115
7.7.2 Injectable Drugs For Allergy Treatment 116
7.7.3 Injectable Drugs For Aesthetic Treatments 117
7.7.4 Injectable Drugs For Hepatitis C 118
7.7.5 Injectable Drugs For Hemophilia 119
8 North America Injectable Drug Delivery Market, By Usage Pattern 121
8.1 Overview 122
8.2 Curative Care 123
8.3 Immunizations 124
8.4 Other Usage Pattern 125
9 North America Injectable Drug Delivery Market, By Mode Of Administration 126
9.1 Overview 127
9.2 Skin 128
9.3 Circulatory/ Muskoskeletal 128
9.4 Organs 129
9.5 Central Nervous System 130
?
10 North America Injectable Drug Delivery Market, By End User 131
10.1 Overview 132
10.2 Hospitals And Clinics 134
10.3 Home Healthcare Settings 134
10.4 Research Laboratories 134
10.5 Pharmaceutical And Biotechnological Companies 135
10.6 Other End Users 136
11 North America Injectable Drug Delivery Market, By Distribution Channel 137
11.1 Overview 138
11.1.1 Hospital Pharmacy 139
11.1.2 Pharmacy Stores 139
11.1.3 Direct Tender 139
11.1.4 Online Pharmacy 139
12 North America Injectable Drug Dilivery Market By Geography 141
12.1.1 U.S. Injectable Drug Delivery Market 158
12.1.2 Canada Injectable Drug Delivery Market 173
12.1.3 Mexico Injectable Drug Delivery Market 189
13 North America Injectable Drug Delivery Market, Company Share 205
13.1 Company Share Analysis; North America 205
14 Company Profiles 206
14.1 Becton, Dickinson And Company 206
14.1.1 Company Overview 206
14.1.1.1 Drivers Explained 207
14.1.1.2 Weaknesses Explained 207
14.1.1.3 Oppurtunities Explained 208
14.1.1.4 Threats Explained 208
14.1.2 Product Portfolio 209
14.1.3 Recent Developments 210
14.2 Pfizer 211
14.2.1 Company Overview 211
14.2.1.1 Drivers Explained 212
14.2.1.2 Weaknesses Explained 213
14.2.1.3 Oppurtunities Explained 213
14.2.1.4 Threats Explained 214
14.2.2 Product Portfolio 215
14.2.3 Recent Developments 216
14.3 Baxter International 217
14.3.1 Company Overview 217
14.3.1.1 Drivers Explained 218
14.3.1.2 Weaknesses Explained 219
14.3.1.3 Oppurtunities Explained 219
14.3.1.4 Threats Explained 220
14.3.2 Product Portfolio 221
14.3.3 Recent Developments 222
14.4 Gerresheimer Ag 223
14.4.1 Company Overview 223
14.4.2 Product Portfolio 224
14.4.3 Recent Developments 224
14.5 Schott Ag Inc. 225
14.5.1 Company Overview 225
14.5.2 Product Portfolio 226
14.5.3 Recent Developments 226
14.6 Alkermes Inc. 227
14.6.1 Company Overview 227
14.6.2 Product Portfolio 228
14.6.3 Recent Developments 228
14.7 Antares Pharma 229
14.7.1 Company Overview 229
14.7.2 Product Portfolio 230
14.7.3 Recent Developments 230
14.8 Bespak (Subsidiary Of Consort Medical Company) 232
14.8.1 Company Overview 232
14.8.2 Product Portfolio 233
14.8.3 Recent Developments 233
14.9 Elcam Medical 234
14.9.1 Company Overview 234
14.9.2 Product Portfolio 234
14.9.3 Recent Developments 234
14.10 Eli Lilly And Company 235
14.10.1 Company Overview 235
14.10.1.1 Drivers Explained 236
14.10.1.2 Weaknesses Explained 237
14.10.1.3 Oppurtunities Explained 237
14.10.1.4 Threats Explained 238
14.10.2 Product Portfolio 239
14.10.3 Recent Developments 240
14.11 Haselmeier 241
14.11.1 Company Overview 241
14.11.2 Product Portfolio 241
14.11.3 Recent Developments 242
14.12 Mylan N.V. 243
14.12.1 Company Overview 243
14.12.2 Product Portfolio 243
14.12.3 Recent Developments 244
14.13 Novo Nordisk 245
14.13.1 Company Overview 245
14.13.2 Product Portfolio 246
14.13.3 Recent Developments 247
14.14 Owen Mumford Ltd 248
14.14.1 Company Overview 248
14.14.2 Product Portfolio 249
14.14.3 Recent Developments 249
14.15 Sandoz International Gmbh 250
14.15.1 Company Overview 250
14.15.2 Product Portfolio 251
14.15.3 Recent Developments 251
14.16 Sanofi 252
14.16.1 Company Overview 252
14.16.2 Product Portfolio 253
14.16.3 Recent Developments 254
14.17 Terumo Corporation 255
14.17.1 Company Overview 255
14.17.2 Product Portfolio 256
14.17.3 Recent Developments 256
14.18 Teva Pharmaceutical 258
14.18.1 Company Overview 258
14.18.1.1 Drivers Explained 259
14.18.1.2 Weaknesses Explained 259
14.18.1.3 Oppurtunities Explained 260
14.18.1.4 Threats Explained 261
14.18.2 Product Portfolio 262
14.18.3 Recent Developments 263
14.19 West Pharmaceutical Services, Inc 264
14.19.1 Company Overview 264
14.19.2 Product Portfolio 265
14.19.3 Recent Developments 266
14.20 Ypsomed Holding Ag 267
14.20.1 Company Overview 267
14.20.2 Product Portfolio 268
14.20.3 Recent Developments 268
15 Related Reports 269